Skip to main content
. 2022 Mar 29;11(7):e023776. doi: 10.1161/JAHA.121.023776

Figure 1. Cumulative incidence of primary end point and acute coronary syndrome between vasodilator group and no vasodilator group.

Figure 1

Composite outcome of cardiac death, acute coronary syndrome, and new‐onset arrhythmia before (A) and after (C) propensity score matching; acute coronary syndrome before (B) and after (D) propensity score matching.